Diversified Trust Co Acquires 15,487 Shares of IQVIA Holdings Inc. $IQV

Diversified Trust Co increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 57.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,579 shares of the medical research company’s stock after purchasing an additional 15,487 shares during the period. Diversified Trust Co’s holdings in IQVIA were worth $8,087,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in IQV. Alliancebernstein L.P. increased its position in IQVIA by 0.6% during the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after acquiring an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in IQVIA in the second quarter worth approximately $515,772,000. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after acquiring an additional 581,157 shares during the last quarter. Nordea Investment Management AB grew its position in shares of IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares during the period. Finally, Lazard Asset Management LLC raised its holdings in IQVIA by 6.1% in the 2nd quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock worth $294,145,000 after purchasing an additional 107,500 shares during the period. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Price Performance

Shares of NYSE:IQV opened at $227.08 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The firm has a market cap of $38.67 billion, a price-to-earnings ratio of 31.15, a P/E/G ratio of 2.51 and a beta of 1.37. The firm has a fifty day moving average price of $221.47 and a 200 day moving average price of $195.83. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $234.29.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The business’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IQV. Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. BMO Capital Markets assumed coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective for the company. UBS Group raised their target price on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Finally, Stifel Nicolaus raised their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $243.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.